Overview

Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of KW-3902IV compared to placebo and to determine the diuretic effect of KW-3902IV compared to placebo in patients hospitalized with volume overload due to CHF who are refractory to high dose diuretic therapy.
Phase:
Phase 2
Details
Lead Sponsor:
NovaCardia, Inc.
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Diuretics
Rolofylline